AbbVie Inc.

NYSE:ABBV

Drug Manufacturers - General

Healthcare
$285.96 -2.10%

-$4.65 today

Market cap
$505.47B
Beta
0.31
P/E (TTM)
105.6
EPS (TTM)
$2.05
Dividend yield
3.11%
52W Low $181.73High $244.81

Volume 4.73M

Average 6.47M

ABBV Net Income

Bottom-line profit, the starting point for calculating cash from operations.

AbbVie Inc.NYSE: ABBV

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $3.62B rose 284.3% year over year, ahead of the +66.4% change in trailing-twelve-month net income. Sequentially, it rose 418.8% from the prior quarter. Over 3 fiscal years it compounded at -29.1% a year.

Context

  • Net income amounted to 6.9% of revenue in FY2025, down 0.7 pp from a year earlier.
  • Net income increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 19 analysts of $24.82B (+487.2%) for the fiscal year ending Dec 2026, a step up from the -1.4% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$3.62B+418.8% QoQ
Last fiscal yearDec 2025
$4.23B-1.4% YoY
LTMJun 2026
$6.32B+66.4% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+284.3%+3412.2%+3128.0 pp
1 year-1.4%+487.2%+488.6 pp
3-year CAGR-29.1%+96.4%+125.4 pp
5-year CAGR+54.7%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
4.23B USD
Year-over-year change
-1.4%
4-year CAGR
-22.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ABBV compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +66.4% is the 3rd highest of 10, against a peer median of +15.4%.
  • Net income amounts to 9.8% of revenue for ABBV, versus a peer median of 18.9%.
ABBV Competitors
Net Income for ABBV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LLYEli Lilly and CompanyLTM Jun 2026$26.71B USD+93.6%+49.0%33.5%
JNJJohnson & JohnsonLTM Sep 2026$16.1B USD-35.9%+14.3%16.2%
NVSNovartis AGLTM Jun 2026$12.76B USD-6.4%+32.5%22.9%
AZNAstraZeneca PLCLTM Sep 2026$11.82B USD+15.4%+59.9%19.0%
BMYBristol-Myers Squibb CompanyLTM Jun 2026$9.27B USD+83.1%+3.6%18.9%
AMGNAmgen Inc.LTM Jun 2026$8.74B USD+32.1%+5.6%22.9%
ABBVAbbVie Inc.LTM Jun 2026$6.32B USD+66.4%-29.1%9.8%
GSKGSK plcLTM Jun 2026£5.62B GBP+41.0%+0.6%16.9%
PFEPfizer Inc.LTM Jun 2026$4.37B USD-59.4%-37.2%6.9%
MRKMerck & Co., Inc.LTM Jun 2026$3.17B USD-80.7%+7.9%4.8%
Peer median (excluding ABBV) —+15.4%+7.9%18.9%

Competitors are the stored peer set for ABBV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income11.55B11.85B4.82B4.29B4.23B
Depreciation & Amortization8.52B8.47B8.7B8.39B8.14B
Deferred Income Tax(898M)(1.93B)(2.89B)(1.45B)(492M)
Stock-Based Compensation692M671M747M911M955M
Change in Working Capital(1.32B)(258M)2.81B(2.78B)(2.36B)
Accounts Receivables(1.32B)(1.46B)66M207M(1.49B)
Inventory(142M)(686M)(417M)(319M)(234M)
Accounts Payables1.63B1.61B3.84B177M951M
Other Working Capital(1.49B)278M(676M)(2.85B)(1.59B)
Other Non-Cash Items4.24B6.15B8.65B9.45B8.6B
Operating Cash Flow22.78B24.94B22.84B18.81B19.03B
Capital Expenditures(787M)(695M)(777M)(974M)(1.21B)
Acquisitions (Net)(1.9B)(794M)(1.22B)(17.49B)(204M)
Purchases of Investments(119M)(1.44B)(77M)(73M)(35M)
Sales of Investments98M1.53B55M555M76M
Other Investing Activities366M774M13M(2.84B)(5.27B)
Investing Cash Flow(2.34B)(623M)(2.01B)(20.82B)(6.64B)
Debt Repayment(8.41B)(12.43B)(4.15B)7.35B(327M)
Common Stock Issued0000172M
Common Stock Repurchased(934M)(1.49B)(1.97B)(1.71B)(980M)
Dividends Paid(9.26B)(10.04B)(10.54B)(11.03B)(11.66B)
Other Financing Activities(430M)(840M)(562M)172M68M
Financing Cash Flow(19.04B)(24.8B)(17.22B)(5.21B)(12.72B)
Effect of Forex Changes(97M)(62M)5M(65M)42M
Net Change in Cash1.3B(545M)3.61B(7.29B)(295M)
Free Cash Flow21.99B24.25B22.06B17.83B17.82B

AbbVie Inc.

NYSE:ABBV

Intrinsic Alpha fair value

Locked

Current Price

$285.96

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.